Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-03

AUTHORS

Laura Pala, Ilaria Dicembrini, Edoardo Mannucci

ABSTRACT

Meta-analyses of clinical trials comparing CSII with traditional insulin injections usually show a small, but significant advantage of CSII with respect to HbA1c and risk of severe hypoglycemia. On the other hand, CSII is associated with a small, but relevant risk of ketoacidosis, mainly due to malfunction of insulin pump and/or catheter occlusion. During last time, the technology of insulin pumps and infusion sets has improved as the profound evolution in type and schemes with traditional insulin injections. Aim of the present study is to update previous meta-analyses comparing CSII with traditional insulin injections in subjects with type 1 diabetes. Specific subgroup analyses were designed for assessing the effects of CSII in comparison with basal-bolus MDI, with short-acting analogues as bolus and long-acting analogues as basal insulin. In addition, an exploratory analysis was performed to verify the effect of CSII in insulin-naïve patients with type 1 diabetes. The present analysis includes all randomized clinical trials comparing CSII with traditional injections in type 1 diabetes, with a duration of at least 12 weeks. Animal studies were excluded, whereas no language or date restriction was imposed. If duplicate publications of a single trial were present, the paper containing more adequate information was considered as principal publication. In trials comparing CSII with basal-bolus MDI, performed before the introduction of rapid-acting analogues, regular human insulin was used for CSII, and as prandial insulin in control groups. CSII was associated with a significant reduction of A1c, in comparison with MDI, irrespective of the use of either human insulin or rapid-acting analogues. However, in trials with rapid-acting analogue the advantage of CSII was significantly smaller than in trials with regular human insulin (HbA1c difference: - 0.29[- 0.46; - 0.13] vs - 1.93[- 1.84; - 0.42]%; p = 0.02). Different rapid-acting analogues provided similar results (HbA1c reduction vs MDI: - 0.25 [- 0.48; - 0.02]%, p = 0.03, and - 0.29 [- 0.49; - 0.09]%, p = 0.005, for lispro and aspart, respectively). In addition, in trials comparing CSII with basal-bolus MDI, CSII reduced HbA1c to a similar extent irrespective of the use of either NPH or long-acting analogues as basal insulin in the control groups (HbA1c reduction vs MDI: - 0.31 [- 0.55; - 0.06]%, p = 0.01, and - 0.20 [- 0.38; - 0.03]%, p = 0.02, for NPH and long-acting analogues, respectively. With respect to severe hypoglycemia, CSII did not produce a significant reduction of risk in comparison with traditional insulin injections. Conversely, CSII was associated with a significant increase in the incidence of reported diabetic ketoacidosis (DKA). Notably, the increased risk of DKA was significant in trials comparing CSII with conventional insulin therapy, whereas only a nonsignificant trend toward an increased risk was observed in comparisons with basal-bolus MDI. Only two trials comparing CSII with basal-bolus MDI, both using rapid-acting analogues, were performed on insulin-naïve type 1 diabetic patients. When those two trials were analyzed separately, CSII did not produce any relevant effect on HbA1c (difference from control: - 0.10[- 0.38; + 0.17]%; p = 0.46). No meta-analysis could be performed on either severe hypoglycemia or DKA, which were not reported by one of the two trials. CSII seems to produce a small improvement in HbA1c in patients with type 1 diabetes inadequately controlled with MDI. This apparent effect, which could be partly due to publication bias, is smaller when MDI is properly performed using basal-bolus schemes with short-acting insulin analogues. Other outcomes different from HbA1c (such as quality of life) could be relevant for the choice of CSII instead of MDI. In addition, further studies are needed to better define the profile of patients who could benefit most from CSII. More... »

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00592-019-01326-5

DOI

http://dx.doi.org/10.1007/s00592-019-01326-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113182419

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30945047


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Department of Diabetology, Careggi Hospital, Florence, Italy. laura.pala@aouc.unifi.it."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pala", 
        "givenName": "Laura", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Florence", 
          "id": "https://www.grid.ac/institutes/grid.8404.8", 
          "name": [
            "Department of Diabetology, Careggi Hospital, Florence, Italy.", 
            "University of Florence, Florence, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dicembrini", 
        "givenName": "Ilaria", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Florence", 
          "id": "https://www.grid.ac/institutes/grid.8404.8", 
          "name": [
            "Department of Diabetology, Careggi Hospital, Florence, Italy.", 
            "University of Florence, Florence, Italy."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mannucci", 
        "givenName": "Edoardo", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejm199309303291401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004144761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1399-5448.2008.00390.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010159571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.b2700", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015745369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.081041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018357349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.081041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018357349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmct1113948", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027715783"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabres.2009.05.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033317255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.324.7339.705", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040697652"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.h4188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041828430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-008-0974-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042010617", 
          "https://doi.org/10.1007/s00125-008-0974-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-008-0974-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042010617", 
          "https://doi.org/10.1007/s00125-008-0974-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-008-0974-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042010617", 
          "https://doi.org/10.1007/s00125-008-0974-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd005103.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042290924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-5491.2008.02486.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044913680"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/dmrr.2653", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048267321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/152091503322641006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059211947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2008-1415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064290848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta14110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139138"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-157-5-201209040-00508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073713154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmjopen-2017-016587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090945355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcjd.2017.10.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103187131"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0194801", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103236332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc18-su09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106289956"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-03", 
    "datePublishedReg": "2019-04-03", 
    "description": "Meta-analyses of clinical trials comparing CSII with traditional insulin injections usually show a small, but significant advantage of CSII with respect to HbA1c and risk of severe hypoglycemia. On the other hand, CSII is associated with a small, but relevant risk of ketoacidosis, mainly due to malfunction of insulin pump and/or catheter occlusion. During last time, the technology of insulin pumps and infusion sets has improved as the profound evolution in type and schemes with traditional insulin injections. Aim of the present study is to update previous meta-analyses comparing CSII with traditional insulin injections in subjects with type 1 diabetes. Specific subgroup analyses were designed for assessing the effects of CSII in comparison with basal-bolus MDI, with short-acting analogues as bolus and long-acting analogues as basal insulin. In addition, an exploratory analysis was performed to verify the effect of CSII in insulin-na\u00efve patients with type 1 diabetes. The present analysis includes all randomized clinical trials comparing CSII with traditional injections in type 1 diabetes, with a duration of at least 12 weeks. Animal studies were excluded, whereas no language or date restriction was imposed. If duplicate publications of a single trial were present, the paper containing more adequate information was considered as principal publication. In trials comparing CSII with basal-bolus MDI, performed before the introduction of rapid-acting analogues, regular human insulin was used for CSII, and as prandial insulin in control groups. CSII was associated with a significant reduction of A1c, in comparison with MDI, irrespective of the use of either human insulin or rapid-acting analogues. However, in trials with rapid-acting analogue the advantage of CSII was significantly smaller than in trials with regular human insulin (HbA1c difference: -\u20090.29[-\u20090.46; -\u20090.13] vs -\u20091.93[-\u20091.84; -\u20090.42]%; p\u2009=\u20090.02). Different rapid-acting analogues provided similar results (HbA1c reduction vs MDI: -\u20090.25 [-\u20090.48; -\u20090.02]%, p\u2009=\u20090.03, and -\u20090.29 [-\u20090.49; -\u20090.09]%, p\u2009=\u20090.005, for lispro and aspart, respectively). In addition, in trials comparing CSII with basal-bolus MDI, CSII reduced HbA1c to a similar extent irrespective of the use of either NPH or long-acting analogues as basal insulin in the control groups (HbA1c reduction vs MDI: -\u20090.31 [-\u20090.55; -\u20090.06]%, p\u2009=\u20090.01, and -\u20090.20 [-\u20090.38; -\u20090.03]%, p\u2009=\u20090.02, for NPH and long-acting analogues, respectively. With respect to severe hypoglycemia, CSII did not produce a significant reduction of risk in comparison with traditional insulin injections. Conversely, CSII was associated with a significant increase in the incidence of reported diabetic ketoacidosis (DKA). Notably, the increased risk of DKA was significant in trials comparing CSII with conventional insulin therapy, whereas only a nonsignificant trend toward an increased risk was observed in comparisons with basal-bolus MDI. Only two trials comparing CSII with basal-bolus MDI, both using rapid-acting analogues, were performed on insulin-na\u00efve type 1 diabetic patients. When those two trials were analyzed separately, CSII did not produce any relevant effect on HbA1c (difference from control: -\u20090.10[-\u20090.38; +\u20090.17]%; p\u2009=\u20090.46). No meta-analysis could be performed on either severe hypoglycemia or DKA, which were not reported by one of the two trials. CSII seems to produce a small improvement in HbA1c in patients with type 1 diabetes inadequately controlled with MDI. This apparent effect, which could be partly due to publication bias, is smaller when MDI is properly performed using basal-bolus schemes with short-acting insulin analogues. Other outcomes different from HbA1c (such as quality of life) could be relevant for the choice of CSII instead of MDI. In addition, further studies are needed to better define the profile of patients who could benefit most from CSII.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00592-019-01326-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1008525", 
        "issn": [
          "0940-5429", 
          "1432-5233"
        ], 
        "name": "Acta Diabetologica", 
        "type": "Periodical"
      }
    ], 
    "name": "Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30945047"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9200299"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00592-019-01326-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113182419"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00592-019-01326-5", 
      "https://app.dimensions.ai/details/publication/pub.1113182419"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130811_00000006.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00592-019-01326-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00592-019-01326-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00592-019-01326-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00592-019-01326-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00592-019-01326-5'


 

This table displays all metadata directly associated to this object as RDF triples.

134 TRIPLES      20 PREDICATES      44 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00592-019-01326-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nc1d1109297a942f5949ccc73512c2f2b
4 schema:citation sg:pub.10.1007/s00125-008-0974-3
5 https://doi.org/10.1002/14651858.cd005103.pub2
6 https://doi.org/10.1002/dmrr.2653
7 https://doi.org/10.1016/j.diabres.2009.05.020
8 https://doi.org/10.1016/j.jcjd.2017.10.012
9 https://doi.org/10.1056/nejm199309303291401
10 https://doi.org/10.1056/nejmct1113948
11 https://doi.org/10.1089/152091503322641006
12 https://doi.org/10.1111/j.1399-5448.2008.00390.x
13 https://doi.org/10.1111/j.1464-5491.2008.02486.x
14 https://doi.org/10.1136/bmj.324.7339.705
15 https://doi.org/10.1136/bmj.b2700
16 https://doi.org/10.1136/bmj.h4188
17 https://doi.org/10.1136/bmjopen-2017-016587
18 https://doi.org/10.1210/jc.2008-1415
19 https://doi.org/10.1371/journal.pone.0194801
20 https://doi.org/10.1503/cmaj.081041
21 https://doi.org/10.2337/dc18-su09
22 https://doi.org/10.3310/hta14110
23 https://doi.org/10.7326/0003-4819-157-5-201209040-00508
24 schema:datePublished 2019-04-03
25 schema:datePublishedReg 2019-04-03
26 schema:description Meta-analyses of clinical trials comparing CSII with traditional insulin injections usually show a small, but significant advantage of CSII with respect to HbA1c and risk of severe hypoglycemia. On the other hand, CSII is associated with a small, but relevant risk of ketoacidosis, mainly due to malfunction of insulin pump and/or catheter occlusion. During last time, the technology of insulin pumps and infusion sets has improved as the profound evolution in type and schemes with traditional insulin injections. Aim of the present study is to update previous meta-analyses comparing CSII with traditional insulin injections in subjects with type 1 diabetes. Specific subgroup analyses were designed for assessing the effects of CSII in comparison with basal-bolus MDI, with short-acting analogues as bolus and long-acting analogues as basal insulin. In addition, an exploratory analysis was performed to verify the effect of CSII in insulin-naïve patients with type 1 diabetes. The present analysis includes all randomized clinical trials comparing CSII with traditional injections in type 1 diabetes, with a duration of at least 12 weeks. Animal studies were excluded, whereas no language or date restriction was imposed. If duplicate publications of a single trial were present, the paper containing more adequate information was considered as principal publication. In trials comparing CSII with basal-bolus MDI, performed before the introduction of rapid-acting analogues, regular human insulin was used for CSII, and as prandial insulin in control groups. CSII was associated with a significant reduction of A1c, in comparison with MDI, irrespective of the use of either human insulin or rapid-acting analogues. However, in trials with rapid-acting analogue the advantage of CSII was significantly smaller than in trials with regular human insulin (HbA1c difference: - 0.29[- 0.46; - 0.13] vs - 1.93[- 1.84; - 0.42]%; p = 0.02). Different rapid-acting analogues provided similar results (HbA1c reduction vs MDI: - 0.25 [- 0.48; - 0.02]%, p = 0.03, and - 0.29 [- 0.49; - 0.09]%, p = 0.005, for lispro and aspart, respectively). In addition, in trials comparing CSII with basal-bolus MDI, CSII reduced HbA1c to a similar extent irrespective of the use of either NPH or long-acting analogues as basal insulin in the control groups (HbA1c reduction vs MDI: - 0.31 [- 0.55; - 0.06]%, p = 0.01, and - 0.20 [- 0.38; - 0.03]%, p = 0.02, for NPH and long-acting analogues, respectively. With respect to severe hypoglycemia, CSII did not produce a significant reduction of risk in comparison with traditional insulin injections. Conversely, CSII was associated with a significant increase in the incidence of reported diabetic ketoacidosis (DKA). Notably, the increased risk of DKA was significant in trials comparing CSII with conventional insulin therapy, whereas only a nonsignificant trend toward an increased risk was observed in comparisons with basal-bolus MDI. Only two trials comparing CSII with basal-bolus MDI, both using rapid-acting analogues, were performed on insulin-naïve type 1 diabetic patients. When those two trials were analyzed separately, CSII did not produce any relevant effect on HbA1c (difference from control: - 0.10[- 0.38; + 0.17]%; p = 0.46). No meta-analysis could be performed on either severe hypoglycemia or DKA, which were not reported by one of the two trials. CSII seems to produce a small improvement in HbA1c in patients with type 1 diabetes inadequately controlled with MDI. This apparent effect, which could be partly due to publication bias, is smaller when MDI is properly performed using basal-bolus schemes with short-acting insulin analogues. Other outcomes different from HbA1c (such as quality of life) could be relevant for the choice of CSII instead of MDI. In addition, further studies are needed to better define the profile of patients who could benefit most from CSII.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf sg:journal.1008525
31 schema:name Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
32 schema:productId N089e33d85c704823a3f9c21afa03beec
33 N55c2e17e70b6415a86c5d78d4ecb8124
34 N7e55bdee59b54be188689525c08f779c
35 N8473070ee62b4ea4a24a1115a99297f1
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113182419
37 https://doi.org/10.1007/s00592-019-01326-5
38 schema:sdDatePublished 2019-04-11T13:55
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher N1962cfe04fd2439b9a3dcfa8057d82bf
41 schema:url http://link.springer.com/10.1007/s00592-019-01326-5
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N089e33d85c704823a3f9c21afa03beec schema:name dimensions_id
46 schema:value pub.1113182419
47 rdf:type schema:PropertyValue
48 N1962cfe04fd2439b9a3dcfa8057d82bf schema:name Springer Nature - SN SciGraph project
49 rdf:type schema:Organization
50 N3708a350fd494040b263c40f90ba6851 rdf:first Nb83a306f989a4d27935462bca37bf072
51 rdf:rest N4b969103a47d41ad85f955d2d4a139b5
52 N4b969103a47d41ad85f955d2d4a139b5 rdf:first Nea637aa8b5ef4c2582527aabfa3e9b42
53 rdf:rest rdf:nil
54 N55c2e17e70b6415a86c5d78d4ecb8124 schema:name pubmed_id
55 schema:value 30945047
56 rdf:type schema:PropertyValue
57 N7e55bdee59b54be188689525c08f779c schema:name doi
58 schema:value 10.1007/s00592-019-01326-5
59 rdf:type schema:PropertyValue
60 N8473070ee62b4ea4a24a1115a99297f1 schema:name nlm_unique_id
61 schema:value 9200299
62 rdf:type schema:PropertyValue
63 Nb83a306f989a4d27935462bca37bf072 schema:affiliation https://www.grid.ac/institutes/grid.8404.8
64 schema:familyName Dicembrini
65 schema:givenName Ilaria
66 rdf:type schema:Person
67 Nc1d1109297a942f5949ccc73512c2f2b rdf:first Nfd75b13a222f40059a3ac9afa1766d46
68 rdf:rest N3708a350fd494040b263c40f90ba6851
69 Nea637aa8b5ef4c2582527aabfa3e9b42 schema:affiliation https://www.grid.ac/institutes/grid.8404.8
70 schema:familyName Mannucci
71 schema:givenName Edoardo
72 rdf:type schema:Person
73 Nfd75b13a222f40059a3ac9afa1766d46 schema:affiliation https://www.grid.ac/institutes/grid.24704.35
74 schema:familyName Pala
75 schema:givenName Laura
76 rdf:type schema:Person
77 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
78 schema:name Medical and Health Sciences
79 rdf:type schema:DefinedTerm
80 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
81 schema:name Clinical Sciences
82 rdf:type schema:DefinedTerm
83 sg:journal.1008525 schema:issn 0940-5429
84 1432-5233
85 schema:name Acta Diabetologica
86 rdf:type schema:Periodical
87 sg:pub.10.1007/s00125-008-0974-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042010617
88 https://doi.org/10.1007/s00125-008-0974-3
89 rdf:type schema:CreativeWork
90 https://doi.org/10.1002/14651858.cd005103.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042290924
91 rdf:type schema:CreativeWork
92 https://doi.org/10.1002/dmrr.2653 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048267321
93 rdf:type schema:CreativeWork
94 https://doi.org/10.1016/j.diabres.2009.05.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033317255
95 rdf:type schema:CreativeWork
96 https://doi.org/10.1016/j.jcjd.2017.10.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103187131
97 rdf:type schema:CreativeWork
98 https://doi.org/10.1056/nejm199309303291401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004144761
99 rdf:type schema:CreativeWork
100 https://doi.org/10.1056/nejmct1113948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027715783
101 rdf:type schema:CreativeWork
102 https://doi.org/10.1089/152091503322641006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059211947
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1111/j.1399-5448.2008.00390.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010159571
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1111/j.1464-5491.2008.02486.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1044913680
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1136/bmj.324.7339.705 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040697652
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1136/bmj.b2700 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015745369
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1136/bmj.h4188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041828430
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1136/bmjopen-2017-016587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090945355
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1210/jc.2008-1415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064290848
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1371/journal.pone.0194801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103236332
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1503/cmaj.081041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018357349
121 rdf:type schema:CreativeWork
122 https://doi.org/10.2337/dc18-su09 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106289956
123 rdf:type schema:CreativeWork
124 https://doi.org/10.3310/hta14110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139138
125 rdf:type schema:CreativeWork
126 https://doi.org/10.7326/0003-4819-157-5-201209040-00508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073713154
127 rdf:type schema:CreativeWork
128 https://www.grid.ac/institutes/grid.24704.35 schema:alternateName Azienda Ospedaliero-Universitaria Careggi
129 schema:name Department of Diabetology, Careggi Hospital, Florence, Italy. laura.pala@aouc.unifi.it.
130 rdf:type schema:Organization
131 https://www.grid.ac/institutes/grid.8404.8 schema:alternateName University of Florence
132 schema:name Department of Diabetology, Careggi Hospital, Florence, Italy.
133 University of Florence, Florence, Italy.
134 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...